临床试验
再生医学
医学
背景(考古学)
干细胞
食品药品监督管理局
转化医学
干细胞疗法
临床实习
重症监护医学
细胞疗法
药理学
生物信息学
病理
家庭医学
生物
间充质干细胞
古生物学
遗传学
作者
Mohammad Mousaei Ghasroldasht,Jin Seok,Hang-Soo Park,Farzana Begum Liakath Ali,Ayman Al‐Hendy
摘要
Regenerative medicine is a new and promising mode of therapy for patients who have limited or no other options for the treatment of their illness. Due to their pleotropic therapeutic potential through the inhibition of inflammation or apoptosis, cell recruitment, stimulation of angiogenesis, and differentiation, stem cells present a novel and effective approach to several challenging human diseases. In recent years, encouraging findings in preclinical studies have paved the way for many clinical trials using stem cells for the treatment of various diseases. The translation of these new therapeutic products from the laboratory to the market is conducted under highly defined regulations and directives provided by competent regulatory authorities. This review seeks to familiarize the reader with the process of translation from an idea to clinical practice, in the context of stem cell products. We address some required guidelines for clinical trial approval, including regulations and directives presented by the Food and Drug Administration (FDA) of the United States, as well as those of the European Medicine Agency (EMA). Moreover, we review, summarize, and discuss regenerative medicine clinical trial studies registered on the Clinicaltrials.gov website.
科研通智能强力驱动
Strongly Powered by AbleSci AI